A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Emory University
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
University of Alabama at Birmingham
University of Alabama at Birmingham
Hackensack Meridian Health
National Cancer Institute (NCI)
Columbia University
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
Children's Oncology Group
Wake Forest University Health Sciences
Wake Forest University Health Sciences
National Institutes of Health Clinical Center (CC)
Basilea Pharmaceutica
Providence Health & Services
Duke University
Istari Oncology, Inc.
Northwestern University
Spirita Oncology, LLC
City of Hope Medical Center
University of Utah
Northwestern University
Duke University
Dana-Farber Cancer Institute